RNS Number : 6788D
Haleon PLC
11 May 2026
Haleon plc: Aggregated information - transactions in own shares
11 May 2026: Haleon plc (the "Company" or "Haleon") today announces the purchase of 10,205,329 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under its share buyback programme announced on 12 March 2026.
London Stock Exchange
CBOE (UK)/BXE
CBOE (UK)/CXE
Aquis
Date of purchase:
05 May 2026
Number of Shares purchased:
1,439,006
785,136
1,000,448
-
Highest price paid per Share (p):
340.5000
340.0000
340.0000
-
Lowest price paid per Share (p):
332.3000
332.3000
332.3000
-
Volume weighted average price paid per Share (p):
334.8998
334.7846
334.8943
-
Date of purchase:
06 May 2026
Number of Shares purchased:
472,322
274,340
327,453
-
Highest price paid per Share (p):
339.1000
339.1000
339.1000
-
Lowest price paid per Share (p):
335.7000
335.7000
335.7000
-
Volume weighted average price paid per Share (p):
336.8492
336.8585
336.8651
-
Date of purchase:
07 May 2026
Number of Shares purchased:
1,854,310
1,009,106
999,121
-
Highest price paid per Share (p):
337.7000
336.9000
337.7000
-
Lowest price paid per Share (p):
329.8000
330.0000
330.0000
-
Volume weighted average price paid per Share (p):
332.5356
332.1537
332.4612
-
Date of purchase:
08 May 2026
Number of Shares purchased:
851,423
549,334
643,330
-
Highest price paid per Share (p):
333.5000
333.5000
333.5000
-
Lowest price paid per Share (p):
329.4000
329.4000
329.4000
-
Volume weighted average price paid per Share (p):
331.3121
331.0577
331.1967
-
Following the settlement of the above, the Company's registered share capital is 8,880,262,266 ordinary shares of £0.01 each, of which 12,184,020 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,868,078,246 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:
http://www.rns-pdf.londonstockexchange.com/rns/6788D_1-2026-5-8.pdf
This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.
This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.
Enquiries
Investors
Media
Jo Russell
+44 7787 392441
ZoëBird
+44 7736 746167
Rakesh Patel
+44 7552 484646
Victoria Durman
+44 7894 505730
Email:investor-relations@haleon.com
Email:corporate.media@haleon.com
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.
For more information, please visit www.haleon.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
POSBRGDULDGDGLI
